Source: Securities-Hongan Studio
On November 12, Xuantai Pharmaceutical fell 2.23%,The turnover is 130 million yuan, the turnover rate is 7.29%, and the total market value is 5.576 billion yuan.
Calculate the trend of Xuantai Pharmaceutical Market according to the AI model.In terms of short -term trend, it was increased by the main funds for 3 consecutive days.The main force has no control.In terms of medium -term trend, a certain profit chip is accumulated below.Recently, the stock has a phenomenon of suction, but the suction is not strong.Judging from the analysis of public opinion, the market is currently pessimistic.
Analysis of alienation
CRO concept+imitation drug consistency evaluation+Shanghai state -owned enterprise reform+renminbi devaluation benefit+benefitState -owned Enterprise Reform
1. According to the prospectus: The companys CRO service business is mainly a preparation CRO professional service provided by the company and R & D institutions in the process of drug research and development.During the reporting period, CRO service revenue was RMB 56.2548 million, 39.81 million yuan and 48.4531 million yuan, respectively.
2. The companys half -annual report in 2023: The company relies on the "embarrassing drug increase technology platform", "slow -controlled release drug preparation research and development platform" and "fixed -dose drug compound preparation research and development platform"The three major technology platforms continue to invest in research and development of high-tech barriers. At present, the companys products cover antifungal, spiritual, digestive, kidney, and other fields.The company has obtained amprolytic ketone ketone hydrochloride (II), Peropatone ketone hydrochloride, Poachaonazole entericoline, Pronetine hydrochloride, carbonate chipram tablets, PriibarinSlow -release tablets, Sarah Qin -enteric tablet (1.2G), including 7 imitation pharmaceuticals, and other ANDA drug approval. Among them, the first imitation approved by Pothakonazole Entericidine FDA;, Pyrumine hydrochloride (II), Pronetine intestinal illegal release tablets, bear -deolty oxygenic acid capsules, and Sigerine dual -release chip (ii), including NMPA drug approval, of whichPothakangzole entero -soluble tablets approved by NMPA.The company also participated in the research and development of generic drugs such as Marcotett Tanchen and Agezo Pipo enteric capsule, and was approved by Anda.
3. The company belongs to Shanghai state -owned enterprises.The companys final controller is the Shanghai State -owned Assets Supervision and Administration Commission.
4. The companys overseas business accounts for 70%, which benefits from the devaluation of the RMB.
5. The company belongs to state -owned enterprises.The companys final controller is the Shanghai State -owned Assets Supervision and Administration Commission.
(Disclaimer: Analysis of the content is derived from the Internet and does not constitute investment suggestions, investors are requested to independently judge according to different markets)
Fund Analysis
Todays main net inflow of 502,100, accounting for 0%, the industry ranking 76/158, which has been added by the main funds for 3 consecutive days;The inflow of 3.17 billion, the current phenomenon of no continuous increase and decrease, the main trend is not obvious.
The main force holding
The main force is not controlled, and the chips are very distributed veryDiversified, the main turnover was 40.896 million, accounting for 6%of the total turnover.
Technical surface: The average transaction cost of chips is 10.65 yuan
The average transaction cost of the stock chip is 10.65 yuanRecently, the stock has a phenomenon of suction, but the suction is not strong. At present, the stock price is close to the pressure level 12.90, and the pressure level will be prevents the pressure level.
Company profile
Data show that Shanghai Xuantai Medical Technology Co., Ltd.On the first floor of Building, No. 99 Kelu, the establishment date was August 13, 2012, and the listing date on August 25, 2022, the companys main business involved the research and development, production and sales of generic drugs, and CRO services.The latest annual report of main business income composition: product sales income of 69.51%, CRO R & D service 11.82%, equity divided into 8.78%, CMO processing service 7.29%, agency rights income of 2.22%, other (supplementary) 0.19%, self -developed project transfer transferIncome 0.18%.
Shenwan Industry, which is affiliated to Xuantai Pharmaceutical: Medicine, Biological-Chemical Pharmaceutical-Chemical Preparation.The concept sector includes: bears to remove biliary acid, generic drugs, CRO concepts, Shanghai state -owned assets, small plates, etc.
As of September 30, the number of Xuantai pharmaceutical shareholders was 6986.00, a decrease of 0.11%from the previous period; the per capita circulation shares were 20,372, an increase of 1.74%over the previous period.From January to September 2024, Xuantai Pharmaceutical achieved operating income of 363 million yuan, an increase of 69.95%year-on-year; net profit of home mother was 92.573 million yuan, an increase of 110.05%year-on-year.
In terms of dividends, Xuantai Pharmaceutical A shares have cumulative 57.775 million yuan after listing.
In terms of the position of the institution, as of September 30, 2024, among the top ten circulating shareholders of Xuantai Pharmaceutical, the ETF (510810) of China State Shanghai State -owned EnterpriseThe shares were 1.7645 million shares, a decrease of 97,800 shares compared to the previous period.
Risk Tips: The market has risks, and investment needs to be cautious.This article is automatically released by large AI models. Any information that appears in this article (including but not limited to individual stocks, reviews, predictions, charts, indicators, theories, any form of expression, etc.) is only used as a reference, which does not constitute personal investment advice.
